Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor

Chronic bone infection, as attends periodontitis, is often complicated by severe osteolysis. While LPS is believed to be central to the pathogenesis of the osteolytic lesion, the mechanisms by which this bacteria-derived molecule promotes bone resorption are unknown. We find that LPS induces bone ma...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of clinical investigation 1997-09, Vol.100 (6), p.1557-1565
Hauptverfasser: Abu-Amer, Y, Ross, F P, Edwards, J, Teitelbaum, S L
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1565
container_issue 6
container_start_page 1557
container_title The Journal of clinical investigation
container_volume 100
creator Abu-Amer, Y
Ross, F P
Edwards, J
Teitelbaum, S L
description Chronic bone infection, as attends periodontitis, is often complicated by severe osteolysis. While LPS is believed to be central to the pathogenesis of the osteolytic lesion, the mechanisms by which this bacteria-derived molecule promotes bone resorption are unknown. We find that LPS induces bone marrow macrophages (BMMs) to express c-src, a protooncogene product that we demonstrate is a specific marker of commitment to the osteoclast phenotype. We next turned to possible soluble mediators of LPS-induced c-src. Of a number of osteoclastogenic cytokines tested, only TNF-alpha mirrors the c-src-enhancing effect of LPS. Suggesting that LPS augmentation of c-src is TNF-mediated, endotoxin sequentially induces BMM expression of TNF, followed by c-src. TNF and c-src expression, by cultured BMMs derived from LPS-injected mice, reflects duration of exposure to circulating endotoxin, intimating that endotoxin's effect in vivo is also mediated by TNF. Consistent with these findings, thalidomide (which antagonizes TNF action) attenuates c-src induction by LPS. An anti-TNF antibody blocks LPS enhancement of c-src mRNA, validating the cytokine's modulating role in vitro. Using BMMs of TNF receptor-deleted mice, we demonstrate that TNF induction of c-src is transmitted through the cytokine's p55, but not p75, receptor. Most importantly, LPS administered to wild-type mice prompts osteoclast precursor differentiation, manifest by profound osteoclastogenesis in marrow cultured ex vivo, and by a profusion of marrow-residing cells expressing the osteoclast marker tartrate resistant acid phosphatase, in vivo. In contrast, LPS does not substantially enhance osteoclast proliferation in mice lacking the p55TNF receptor, confirming that LPS-induced osteoclastogenesis is mediated by TNF in vivo via this receptor. Thus, therapy targeting TNF and/or its p55 receptor presents itself as a means of preventing the osteolysis of chronic bacterial infection.
doi_str_mv 10.1172/jci119679
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_508337</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79283297</sourcerecordid><originalsourceid>FETCH-LOGICAL-c499t-70aa9b57f68ade38c05c15bd65727592a17c04d31e5327d119063598cb71260a3</originalsourceid><addsrcrecordid>eNpVUctOwzAQ9AFUSuHAByDlhMQh4EccxwcOqOJRVAkOcLYcZ9u6SuJgO5X696S0qkBaabU7s4_RIHRF8B0hgt6vjSVE5kKeoDHGlKRSsOIMnYewxphkGc9GaCSpzAjNxmg9t53rXL0N2piV9raCNETb9LWOUCUuRHCm1iG6JbQQbEiGaKCyv3C5TWLfOJ-0YLzboQtt4lBvrE5sDMkH54kHA93QvECnC10HuDzkCfp6fvqcvqbz95fZ9HGemkzKmAqstSy5WOSFroAVBnNDeFnlXFDBJdVEGJxVjABnVFSDVpwzLgtTCkJzrNkEPez3dn05fGqgjV7XqvO20X6rnLbqP9LalVq6jeK4YEwM8zeHee--ewhRNTYYqGvdguuDEpIWjMod8XZP3GkPHhbHGwSrnRfqbTrbezFwr_8-dWQejGA_qyeJJQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79283297</pqid></control><display><type>article</type><title>Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Abu-Amer, Y ; Ross, F P ; Edwards, J ; Teitelbaum, S L</creator><creatorcontrib>Abu-Amer, Y ; Ross, F P ; Edwards, J ; Teitelbaum, S L</creatorcontrib><description>Chronic bone infection, as attends periodontitis, is often complicated by severe osteolysis. While LPS is believed to be central to the pathogenesis of the osteolytic lesion, the mechanisms by which this bacteria-derived molecule promotes bone resorption are unknown. We find that LPS induces bone marrow macrophages (BMMs) to express c-src, a protooncogene product that we demonstrate is a specific marker of commitment to the osteoclast phenotype. We next turned to possible soluble mediators of LPS-induced c-src. Of a number of osteoclastogenic cytokines tested, only TNF-alpha mirrors the c-src-enhancing effect of LPS. Suggesting that LPS augmentation of c-src is TNF-mediated, endotoxin sequentially induces BMM expression of TNF, followed by c-src. TNF and c-src expression, by cultured BMMs derived from LPS-injected mice, reflects duration of exposure to circulating endotoxin, intimating that endotoxin's effect in vivo is also mediated by TNF. Consistent with these findings, thalidomide (which antagonizes TNF action) attenuates c-src induction by LPS. An anti-TNF antibody blocks LPS enhancement of c-src mRNA, validating the cytokine's modulating role in vitro. Using BMMs of TNF receptor-deleted mice, we demonstrate that TNF induction of c-src is transmitted through the cytokine's p55, but not p75, receptor. Most importantly, LPS administered to wild-type mice prompts osteoclast precursor differentiation, manifest by profound osteoclastogenesis in marrow cultured ex vivo, and by a profusion of marrow-residing cells expressing the osteoclast marker tartrate resistant acid phosphatase, in vivo. In contrast, LPS does not substantially enhance osteoclast proliferation in mice lacking the p55TNF receptor, confirming that LPS-induced osteoclastogenesis is mediated by TNF in vivo via this receptor. Thus, therapy targeting TNF and/or its p55 receptor presents itself as a means of preventing the osteolysis of chronic bacterial infection.</description><identifier>ISSN: 0021-9738</identifier><identifier>DOI: 10.1172/jci119679</identifier><identifier>PMID: 9294124</identifier><language>eng</language><publisher>United States</publisher><subject>3T3 Cells ; Acid Phosphatase - metabolism ; AIDS/HIV ; Animals ; Antigens, CD - genetics ; Antigens, CD - physiology ; Biomarkers - analysis ; Bone Marrow Cells - drug effects ; Bone Marrow Cells - enzymology ; Bone Marrow Cells - metabolism ; Cell Differentiation - drug effects ; Cells, Cultured ; Coculture Techniques ; DNA, Complementary - analysis ; Dose-Response Relationship, Drug ; Genes, src - genetics ; Isoenzymes - metabolism ; Lipopolysaccharides - pharmacology ; Macrophages - drug effects ; Macrophages - metabolism ; Male ; Mice ; Mice, Inbred C3H ; Mice, Knockout ; Osteoclasts - enzymology ; Osteoclasts - metabolism ; Receptors, Tumor Necrosis Factor - genetics ; Receptors, Tumor Necrosis Factor - physiology ; Receptors, Tumor Necrosis Factor, Type I ; RNA, Messenger - analysis ; Tartrate-Resistant Acid Phosphatase ; Thalidomide - pharmacology ; Time Factors ; Tumor Necrosis Factor-alpha - pharmacology</subject><ispartof>The Journal of clinical investigation, 1997-09, Vol.100 (6), p.1557-1565</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c499t-70aa9b57f68ade38c05c15bd65727592a17c04d31e5327d119063598cb71260a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC508337/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC508337/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9294124$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abu-Amer, Y</creatorcontrib><creatorcontrib>Ross, F P</creatorcontrib><creatorcontrib>Edwards, J</creatorcontrib><creatorcontrib>Teitelbaum, S L</creatorcontrib><title>Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor</title><title>The Journal of clinical investigation</title><addtitle>J Clin Invest</addtitle><description>Chronic bone infection, as attends periodontitis, is often complicated by severe osteolysis. While LPS is believed to be central to the pathogenesis of the osteolytic lesion, the mechanisms by which this bacteria-derived molecule promotes bone resorption are unknown. We find that LPS induces bone marrow macrophages (BMMs) to express c-src, a protooncogene product that we demonstrate is a specific marker of commitment to the osteoclast phenotype. We next turned to possible soluble mediators of LPS-induced c-src. Of a number of osteoclastogenic cytokines tested, only TNF-alpha mirrors the c-src-enhancing effect of LPS. Suggesting that LPS augmentation of c-src is TNF-mediated, endotoxin sequentially induces BMM expression of TNF, followed by c-src. TNF and c-src expression, by cultured BMMs derived from LPS-injected mice, reflects duration of exposure to circulating endotoxin, intimating that endotoxin's effect in vivo is also mediated by TNF. Consistent with these findings, thalidomide (which antagonizes TNF action) attenuates c-src induction by LPS. An anti-TNF antibody blocks LPS enhancement of c-src mRNA, validating the cytokine's modulating role in vitro. Using BMMs of TNF receptor-deleted mice, we demonstrate that TNF induction of c-src is transmitted through the cytokine's p55, but not p75, receptor. Most importantly, LPS administered to wild-type mice prompts osteoclast precursor differentiation, manifest by profound osteoclastogenesis in marrow cultured ex vivo, and by a profusion of marrow-residing cells expressing the osteoclast marker tartrate resistant acid phosphatase, in vivo. In contrast, LPS does not substantially enhance osteoclast proliferation in mice lacking the p55TNF receptor, confirming that LPS-induced osteoclastogenesis is mediated by TNF in vivo via this receptor. Thus, therapy targeting TNF and/or its p55 receptor presents itself as a means of preventing the osteolysis of chronic bacterial infection.</description><subject>3T3 Cells</subject><subject>Acid Phosphatase - metabolism</subject><subject>AIDS/HIV</subject><subject>Animals</subject><subject>Antigens, CD - genetics</subject><subject>Antigens, CD - physiology</subject><subject>Biomarkers - analysis</subject><subject>Bone Marrow Cells - drug effects</subject><subject>Bone Marrow Cells - enzymology</subject><subject>Bone Marrow Cells - metabolism</subject><subject>Cell Differentiation - drug effects</subject><subject>Cells, Cultured</subject><subject>Coculture Techniques</subject><subject>DNA, Complementary - analysis</subject><subject>Dose-Response Relationship, Drug</subject><subject>Genes, src - genetics</subject><subject>Isoenzymes - metabolism</subject><subject>Lipopolysaccharides - pharmacology</subject><subject>Macrophages - drug effects</subject><subject>Macrophages - metabolism</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred C3H</subject><subject>Mice, Knockout</subject><subject>Osteoclasts - enzymology</subject><subject>Osteoclasts - metabolism</subject><subject>Receptors, Tumor Necrosis Factor - genetics</subject><subject>Receptors, Tumor Necrosis Factor - physiology</subject><subject>Receptors, Tumor Necrosis Factor, Type I</subject><subject>RNA, Messenger - analysis</subject><subject>Tartrate-Resistant Acid Phosphatase</subject><subject>Thalidomide - pharmacology</subject><subject>Time Factors</subject><subject>Tumor Necrosis Factor-alpha - pharmacology</subject><issn>0021-9738</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUctOwzAQ9AFUSuHAByDlhMQh4EccxwcOqOJRVAkOcLYcZ9u6SuJgO5X696S0qkBaabU7s4_RIHRF8B0hgt6vjSVE5kKeoDHGlKRSsOIMnYewxphkGc9GaCSpzAjNxmg9t53rXL0N2piV9raCNETb9LWOUCUuRHCm1iG6JbQQbEiGaKCyv3C5TWLfOJ-0YLzboQtt4lBvrE5sDMkH54kHA93QvECnC10HuDzkCfp6fvqcvqbz95fZ9HGemkzKmAqstSy5WOSFroAVBnNDeFnlXFDBJdVEGJxVjABnVFSDVpwzLgtTCkJzrNkEPez3dn05fGqgjV7XqvO20X6rnLbqP9LalVq6jeK4YEwM8zeHee--ewhRNTYYqGvdguuDEpIWjMod8XZP3GkPHhbHGwSrnRfqbTrbezFwr_8-dWQejGA_qyeJJQ</recordid><startdate>19970915</startdate><enddate>19970915</enddate><creator>Abu-Amer, Y</creator><creator>Ross, F P</creator><creator>Edwards, J</creator><creator>Teitelbaum, S L</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19970915</creationdate><title>Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor</title><author>Abu-Amer, Y ; Ross, F P ; Edwards, J ; Teitelbaum, S L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c499t-70aa9b57f68ade38c05c15bd65727592a17c04d31e5327d119063598cb71260a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>3T3 Cells</topic><topic>Acid Phosphatase - metabolism</topic><topic>AIDS/HIV</topic><topic>Animals</topic><topic>Antigens, CD - genetics</topic><topic>Antigens, CD - physiology</topic><topic>Biomarkers - analysis</topic><topic>Bone Marrow Cells - drug effects</topic><topic>Bone Marrow Cells - enzymology</topic><topic>Bone Marrow Cells - metabolism</topic><topic>Cell Differentiation - drug effects</topic><topic>Cells, Cultured</topic><topic>Coculture Techniques</topic><topic>DNA, Complementary - analysis</topic><topic>Dose-Response Relationship, Drug</topic><topic>Genes, src - genetics</topic><topic>Isoenzymes - metabolism</topic><topic>Lipopolysaccharides - pharmacology</topic><topic>Macrophages - drug effects</topic><topic>Macrophages - metabolism</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred C3H</topic><topic>Mice, Knockout</topic><topic>Osteoclasts - enzymology</topic><topic>Osteoclasts - metabolism</topic><topic>Receptors, Tumor Necrosis Factor - genetics</topic><topic>Receptors, Tumor Necrosis Factor - physiology</topic><topic>Receptors, Tumor Necrosis Factor, Type I</topic><topic>RNA, Messenger - analysis</topic><topic>Tartrate-Resistant Acid Phosphatase</topic><topic>Thalidomide - pharmacology</topic><topic>Time Factors</topic><topic>Tumor Necrosis Factor-alpha - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abu-Amer, Y</creatorcontrib><creatorcontrib>Ross, F P</creatorcontrib><creatorcontrib>Edwards, J</creatorcontrib><creatorcontrib>Teitelbaum, S L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of clinical investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abu-Amer, Y</au><au>Ross, F P</au><au>Edwards, J</au><au>Teitelbaum, S L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor</atitle><jtitle>The Journal of clinical investigation</jtitle><addtitle>J Clin Invest</addtitle><date>1997-09-15</date><risdate>1997</risdate><volume>100</volume><issue>6</issue><spage>1557</spage><epage>1565</epage><pages>1557-1565</pages><issn>0021-9738</issn><abstract>Chronic bone infection, as attends periodontitis, is often complicated by severe osteolysis. While LPS is believed to be central to the pathogenesis of the osteolytic lesion, the mechanisms by which this bacteria-derived molecule promotes bone resorption are unknown. We find that LPS induces bone marrow macrophages (BMMs) to express c-src, a protooncogene product that we demonstrate is a specific marker of commitment to the osteoclast phenotype. We next turned to possible soluble mediators of LPS-induced c-src. Of a number of osteoclastogenic cytokines tested, only TNF-alpha mirrors the c-src-enhancing effect of LPS. Suggesting that LPS augmentation of c-src is TNF-mediated, endotoxin sequentially induces BMM expression of TNF, followed by c-src. TNF and c-src expression, by cultured BMMs derived from LPS-injected mice, reflects duration of exposure to circulating endotoxin, intimating that endotoxin's effect in vivo is also mediated by TNF. Consistent with these findings, thalidomide (which antagonizes TNF action) attenuates c-src induction by LPS. An anti-TNF antibody blocks LPS enhancement of c-src mRNA, validating the cytokine's modulating role in vitro. Using BMMs of TNF receptor-deleted mice, we demonstrate that TNF induction of c-src is transmitted through the cytokine's p55, but not p75, receptor. Most importantly, LPS administered to wild-type mice prompts osteoclast precursor differentiation, manifest by profound osteoclastogenesis in marrow cultured ex vivo, and by a profusion of marrow-residing cells expressing the osteoclast marker tartrate resistant acid phosphatase, in vivo. In contrast, LPS does not substantially enhance osteoclast proliferation in mice lacking the p55TNF receptor, confirming that LPS-induced osteoclastogenesis is mediated by TNF in vivo via this receptor. Thus, therapy targeting TNF and/or its p55 receptor presents itself as a means of preventing the osteolysis of chronic bacterial infection.</abstract><cop>United States</cop><pmid>9294124</pmid><doi>10.1172/jci119679</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0021-9738
ispartof The Journal of clinical investigation, 1997-09, Vol.100 (6), p.1557-1565
issn 0021-9738
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_508337
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection
subjects 3T3 Cells
Acid Phosphatase - metabolism
AIDS/HIV
Animals
Antigens, CD - genetics
Antigens, CD - physiology
Biomarkers - analysis
Bone Marrow Cells - drug effects
Bone Marrow Cells - enzymology
Bone Marrow Cells - metabolism
Cell Differentiation - drug effects
Cells, Cultured
Coculture Techniques
DNA, Complementary - analysis
Dose-Response Relationship, Drug
Genes, src - genetics
Isoenzymes - metabolism
Lipopolysaccharides - pharmacology
Macrophages - drug effects
Macrophages - metabolism
Male
Mice
Mice, Inbred C3H
Mice, Knockout
Osteoclasts - enzymology
Osteoclasts - metabolism
Receptors, Tumor Necrosis Factor - genetics
Receptors, Tumor Necrosis Factor - physiology
Receptors, Tumor Necrosis Factor, Type I
RNA, Messenger - analysis
Tartrate-Resistant Acid Phosphatase
Thalidomide - pharmacology
Time Factors
Tumor Necrosis Factor-alpha - pharmacology
title Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T22%3A00%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lipopolysaccharide-stimulated%20osteoclastogenesis%20is%20mediated%20by%20tumor%20necrosis%20factor%20via%20its%20P55%20receptor&rft.jtitle=The%20Journal%20of%20clinical%20investigation&rft.au=Abu-Amer,%20Y&rft.date=1997-09-15&rft.volume=100&rft.issue=6&rft.spage=1557&rft.epage=1565&rft.pages=1557-1565&rft.issn=0021-9738&rft_id=info:doi/10.1172/jci119679&rft_dat=%3Cproquest_pubme%3E79283297%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79283297&rft_id=info:pmid/9294124&rfr_iscdi=true